mTOR signaling pathway in cancer targets photodynamic therapy in vitro

Sandra M. Ayuk, Heidi Abrahamse

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein kinase. It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis. Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment. Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant lesions. This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy. It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.

Original languageEnglish
Article number431
Issue number5
Publication statusPublished - May 2019


  • Cancers
  • Inhibitors
  • MTOR
  • Photodynamic therapy

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'mTOR signaling pathway in cancer targets photodynamic therapy in vitro'. Together they form a unique fingerprint.

Cite this